Palisade Bio (PALI) Stock Price, News & Analysis

Company Overview

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

Key Stats

• Today's Range: $0.67 to $0.72
• 50-Day Range: $0.69 to $1.76
• 52-Week Range: $0.66 to $9.65
• Volume: 44,867 shs
• Average Volume: 760,736 shs
• Market Capitalization: $1.91 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.00
• Consensus Rating: Buy

Palisade Bio Stock Analysis - MarketRank™

Palisade Bio scored higher than 48% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Palisade Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Palisade Bio has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Palisade Bio are expected to grow in the coming year, from ($12.43) to ($2.99) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Palisade Bio is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Palisade Bio is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Palisade Bio has a P/B Ratio of 0.04. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.40% of the float of Palisade Bio has been sold short.

Short Interest Ratio / Days to Cover

Palisade Bio has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Palisade Bio has recently increased by 38.45%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Palisade Bio does not currently pay a dividend.

Dividend Growth

Palisade Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.40% of the float of Palisade Bio has been sold short.

Short Interest Ratio / Days to Cover

Palisade Bio has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Palisade Bio has recently increased by 38.45%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 1.50

News Sentiment

Palisade Bio has a news sentiment score of 1.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Palisade Bio this week, compared to 2 articles on an average week.

Search Interest

Only 8 people have searched for PALI on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.

MarketBeat Follows

2 people have added Palisade Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Palisade Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.28% of the stock of Palisade Bio is held by insiders.

Percentage Held by Institutions

Only 11.79% of the stock of Palisade Bio is held by institutions.

PALI Stock Analysis - Frequently Asked Questions

How have PALI shares performed this year?

Palisade Bio's stock was trading at $1.65 at the beginning of 2025. Since then, PALI shares have decreased by 58.2% and is now trading at $0.6901.
View the best growth stocks for 2025 here.

How were Palisade Bio's earnings last quarter?

Palisade Bio, Inc. (NASDAQ:PALI) issued its earnings results on Monday, March, 24th. The company reported ($0.69) earnings per share for the quarter, beating analysts' consensus estimates of ($2.39) by $1.70.

When did Palisade Bio's stock split?

Palisade Bio shares reverse split before market open on Monday, April 8th 2024. The 1-15 reverse split was announced on Monday, April 8th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Who are Palisade Bio's major shareholders?

Palisade Bio's top institutional shareholders include Cetera Investment Advisers (2.53%). Insiders that own company stock include John David Finley, Thomas Hallam, Donald Allen Williams, Michael John Dawson and Robert J Trenschel.
View institutional ownership trends.

How do I buy shares of Palisade Bio?

Shares of PALI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Palisade Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Palisade Bio investors own include Onconova Therapeutics (ONTX), Sesen Bio (SESN), Iterum Therapeutics (ITRM), Outlook Therapeutics (OTLK), Bionano Genomics (BNGO), PayPal (PYPL) and Tesla (TSLA).

Company Calendar

• Last Earnings: 3/24/2025
• Today: 3/25/2025
• Next Earnings (Estimated): 3/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PALI
• CIK: 1357459
• Web: www.palisadebio.com
• Phone: (858) 704-4900
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $23.00
• High Stock Price Target: $38.00
• Low Stock Price Target: $8.00
• Potential Upside/Downside: +3,232.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($13.98)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-12,300,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -148.51%
• Return on Assets: -115.16%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.31
• Quick Ratio: 3.31

Sales & Book Value

• Annual Sales: $250,000.00
• Price / Sales: 7.64
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $18.29 per share
• Price / Book: 0.04

Miscellaneous

• Outstanding Shares: 2,766,000
• Free Float: 2,675,000
• Market Cap: $1.91 million
• Optionable: Not Optionable
• Beta: 1.49